The estimated Net Worth of Kurt Zumwalt is at least $552 mil dollars as of 15 August 2023. Mr. Zumwalt owns over 13,369 units of Omeros stock worth over $244,746 and over the last 5 years he sold OMER stock worth over $307,182. In addition, he makes $0 as Independent Director at Omeros.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Zumwalt OMER stock SEC Form 4 insiders trading
Kurt has made over 2 trades of the Omeros stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 13,369 units of OMER stock worth $72,059 on 15 August 2023.
The largest trade he's ever made was selling 13,369 units of Omeros stock on 15 August 2023 worth over $72,059. On average, Kurt trades about 750 units every 22 days since 2020. As of 15 August 2023 he still owns at least 66,507 units of Omeros stock.
You can see the complete history of Mr. Zumwalt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kurt Zumwalt biography
Kurt Zumwalt serves as Independent Director of the Company. He has served on our board of directors since February 2020. Mr. Zumwalt served as treasurer at Amazon.com, Inc. from 2014 until August 2019, where he led global cash and portfolio management, debt financing, foreign exchange, insurance and treasury-related technology infrastructure. Prior to joining Amazon.com as assistant treasurer in 2004, he served in various financial and treasury roles at PACCAR, ProBusiness Services, Wind River Systems and Intel Corporation. He also serves on the board of directors of Ranpak Holdings Corp., a manufacturer of sustainable packaging, as well as the United States Tennis Association and of the USTA Foundation. Mr. Zumwalt received a B.A. in economics and political science from the University of Pennsylvania and an M.B.A. in finance and accounting from the University of Washington. Our nominating and governance committee has concluded that Mr. Zumwalt should continue to serve on the board of directors based on his expertise in finance, business and banking as well as his significant relationships with major banks and financial institutions.
How old is Kurt Zumwalt?
Kurt Zumwalt is 51, he's been the Independent Director of Omeros since 2020. There are 25 older and 4 younger executives at Omeros. The oldest executive at Omeros Corporation is Ray Aspiri, 83, who is the Independent Director.
What's Kurt Zumwalt's mailing address?
Kurt's mailing address filed with the SEC is RANPAK HOLDINGS CORP., 7990 AUBURN ROAD, CONCORD TOWNSHIP, OH, 44077.
Insiders trading at Omeros
Over the last 15 years, insiders at Omeros have traded over $719,810 worth of Omeros stock and bought 141,095 units worth $829,835 . The most active insiders traders include Gregory A Md Demopulos, Marcia S. Kelbon, eDaniel K Spiegelman. On average, Omeros executives and independent directors trade stock every 53 days with the average trade being worth of $97,792. The most recent stock trade was executed by Gregory A Md Demopulos on 17 November 2023, trading 15,000 units of OMER stock currently worth $25,200.
What does Omeros do?
omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
What does Omeros's logo look like?
Complete history of Mr. Zumwalt stock trades at Omeros e Ranpak Corp
Omeros executives and stock owners
Omeros executives and other stock owners filed with the SEC include:
-
Gregory Demopulos,
Chairman of the Board, President, Chief Executive Officer -
Dr. Gregory A. Demopulos,
Co-Founder, Chairman, CEO & Pres -
Dr. Gregory A. Demopulos M.D.,
Co-Founder, Chairman, CEO & Pres -
Michael Jacobsen,
Chief Accounting Officer, Vice President - Finance, Treasurer -
Peter Cancelmo,
Vice President, General Counsel, Secretary -
Michael A. Jacobsen,
Chief Accounting Officer, VP of Fin. & Treasurer -
Peter B. Cancelmo J.D.,
VP, Gen. Counsel & Corp. Sec. -
Thomas Bumol,
Independent Director -
Thomas Cable,
Lead Independent Director -
Ray Aspiri,
Independent Director -
Arnold Hanish,
Independent Director -
Leroy Hood,
Independent Director -
Rajiv Shah,
Independent Director -
Peter Demopulos,
Director -
Kurt Zumwalt,
Independent Director -
Timothy Duffy,
Vice President - Business Development -
J. Steven Whitaker,
Vice President, Chief Medical Officer -
Tina Quinton,
Vice President - Patents -
Catherine Melfi,
Vice President - Regulatory Affairs & Quality Systems, Chief Regulatory Officer -
Bruce Meiklejohn,
Vice President - Chemistry, Manufacturing and Controls -
Daniel Kirby,
Vice President, Chief Commercial Officer -
Christopher Bral,
Vice President - Nonclinical Development -
George Gaitanaris,
Chief Scientific Officer, Vice President - Science -
Dr. J. Steven Whitaker J.D., M.D.,
VP of Clinical Devel. & Chief Medical Officer -
Dr. Pamela Pierce Palmer M.D., Ph.D.,
Co-Founder -
Nadia Dac,
Chief Commercial Officer -
Dr. Catherine A. Melfi,
Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems -
Dr. J. Steven Whitaker,
VP of Clinical Devel. & Chief Medical Officer -
Peter W. Williams,
VP of HR -
Dr. George A. Gaitanaris M.D., Ph.D.,
Chief Scientific Officer & VP of Science -
Dr. Pamela Pierce Palmer,
Co-Founder -
Marcia S. Kelbon,
VP Patent and General Counsel -
Diana T. Perkinson,
Director -
Daniel K Spiegelman,
Director -
Jean Philippe Tripet,
Director